Subscribe in seconds and receive Life Sciences Voice's news feed updates in your inbox, on your phone or even read them from your own news page here on follow.it.
You can select the updates using tags or topics and you can add as many websites to your feed as you like.
And the service is entirely free!
Follow Life Sciences Voice: Lifescivoice - News and Insights of Life Sciences Industry
Is this your feed? Claim it!
Already on pace to become a blockbuster in just its third full year on the market, Bristol Myers Squibb’s cardiomyopathy drug Camzyos has posted a clinical win that could open the door to use in a younger patient population.
In a phase 3 trial enrolling 44 adole...
Five months ago, Johnson & Johnson also announced plans to invest $2 billion over the next 10 years to operate a 160,000-square-foot manufacturing facility at Fujifilm Biotechnologies’ biomanufacturing campus in Holly Springs, North Carolina. T...
AbbVie has signed an agreement with China-based biotechnology company RemeGen to obtain the ex-China rights to RC148, a bispecific antibody that targets PD-1 and VEGF. As part of the transaction, AbbVie will make an upfront payment of $650 million to RemeGen.
In addition to the initial payment, the agreement includes the potential for up to $4.95 billion in further pay...
EBV+ PTLD The U.S. Food and Drug Administration has declined to approve Atara Biotherapeutics’ cell therapy tabelecleucel for a rare blood cancer, the company said on Monday, a decision that sent its shares down 56% in early trading. The agency issued a comp...
MetaVia has released new phase 1 data on DA-1726, an investigational dual agonist targeting GLP-1 and glucagon, highlighting weight loss and metabolic effects in adults with obesity. The update outlines outcomes from an extended dosing cohort and provides additional details on safety, tolerability, and the company’s development plans.
The phase 1 study enrolled adults ...
